THERAPEUTIC APPLICATIONS OF PERFLUOROCARBON MICROBUBBLES

全氟碳微泡的治疗应用

• 批准号: 2717915
• 负责人: PATRICK L IVERSEN
• 金额: $ 9.88万
• 依托单位: AVI BIOPHARMA, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 1999-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2717915
• 关键词: albumins; antisense nucleic acid; coronary occlusion /thrombosis; fluosol; gene therapy; glucose; hyperplasia; laboratory rat; nonhuman therapy evaluation; oligonucleotides; protooncogene; swine; ultrasound therapy

DESCRIPTION (Adapted from Applicant's Abstract): Transcutaneous ultrasound-mediated destruction (UMD) of microbubbles could potentially be utilized in cardiovascular therapy. The central hypothesis of this project is that UMD of microbubbles can noninvasively (1) target delivery of antisense oligonucleotides, and (2) produce arterial thrombus microfragmentation. Since perfluorocarbon containing dextrose albumin microbubbles (PCMB) have the ability to bind antisense oligonucleotides, UMD of intravenously injected synthetic antisense oliogonucleotides bound to PCMB will be utilized to target their disposition to the myocardium and vascular wall. Subsequent to this, the applicants proposed to examine the potential for intravenous antisense to the protooncogene c-myc bound to PCMB to inhibit neointimal hyperplasia following balloon injury in an animal model. Secondly, the potential for UMD of intravenous PCMB to fragment acute coronary and carotid artery thrombi in the absence of a thrombolytic agent in an animal model will be tested. This three year project will therefore test the ability of UMD of PCMB to non-invasively (a) target gene delivery to the vascular wall, and (b) recanalize coronary and carotid thrombotic occlusions without thrombolytic therapy. Phase III studies will then test the effectiveness of antisense delivery in preventing restenosis following percutaneous revascularization procedures in humans and to improve reperfusion success rates in acute myocardial infarction. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

描述（改编自申请人摘要）：经皮 超声介导的微泡破坏（UMD）可能是 用于心血管治疗。 这个问题的核心假设是 项目是微泡的UMD可以无创地（1）靶向递送 反义寡核苷酸，和（2）产生动脉血栓 微碎片 由于含有葡萄糖白蛋白的全氟化碳 微泡（PCMB）具有结合反义寡核苷酸的能力， 静脉注射合成反义寡核苷酸结合的UMD 将利用PCMB将其定位于心肌， 血管壁 此后，申请人建议审查 潜在的静脉内反义的原癌基因c-myc结合， PCMB抑制球囊损伤后的新生内膜增生 动物模型 其次，静脉内PCMB的UMD的可能性， 急性冠状动脉和颈动脉血栓碎片， 将在动物模型中测试血栓溶解剂。 这三年 因此，该项目将测试PCMB的UMD非侵入性 (a)靶向基因递送至血管壁，和（B）再通冠状动脉 和没有溶栓治疗的颈动脉血栓性闭塞。 III期 然后，研究将测试反义递送在以下方面的有效性： 预防经皮血运重建术后再狭窄 并提高急性心肌梗死再灌注成功率 梗塞 拟议商业应用：不可用